Daily Archives: 30/10/2010

Fabry disease and Drug Development

Fabry disease is rare inherited enzyme deficiency disease and it is named after its discoverer  Johannes Fabry.  A deficiency of the enzyme alpha galactosidase A due to mutation causes a glycolipid known as globotriaosylceramide (abbreviated as Gb3, GL-3, or ceramide trihexoside) to … Continue reading

Posted in Uncategorized | 2 Comments

CI & Patent News 30/10/2010

1) Astellas Pharma has submitted marketing authorization application to Japan MOH for approval of Degarelix for treating prostate cancer Degarelix is Gonadtropin releasing hormone (GnRH) blocker. Degarelix was approved for the treatment of prostate cancer by the U.S. Food and Drug … Continue reading

Posted in Daily interesting IP news | Leave a comment